Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The New Oncology Model Created to Improve Cancer Care

For anyone working in the oncology field, a highly anticipated change set to take place will be one of the biggest transitions in recent years. Last year, it was announced that the Oncology Care Model (OCM) will be phased out and succeeded with the Enhanced Oncology Model (EOM). This new model will go into effect…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Carevive on MarketScale.

Share
The New Oncology Model Created to Improve Cancer Care

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

For anyone working in the oncology field, a highly anticipated change set to take place will be one of the biggest transitions in recent years. Last year, it was announced that the Oncology Care Model (OCM) will be phased out and succeeded with the Enhanced Oncology Model (EOM). This new model will go into effect in July 2023 and help improve care for cancer patients.

What are the people who work in the oncology field most looking forward to with the forthcoming new model implementation? And what are their expectations for cancer care?

In the latest episode of “Oncology and Technology,” host Tyler Kern sat down to interview with several members of the Carevive team, John Elliot, VP of Sales; Reesa Sherin, Clinical Strategist; and April Boyd, Clinical Product Manager, mostly about the state of the oncology, and what current trends will remain or seeing advancements next year.

Kern, Elliot, Sherin, and Boyd also talked about …

  1. Educational events held in preparation for the shift to EOM
  2. What clinicians will value in terms of the new models and how they expect to implement
  3. How the shift will change oncology and cancer patient care

“The big shift, I think, just in healthcare broadly and then specifically to oncology, has been continued evaluation and how health systems and cancer centers are evaluating a shift to value-based care from the traditional … service,” said Elliot.

John Elliot is the Vice President of Sales at Carevive. He has been with the company for almost four years and held a previous senior position at Cerner Corporation. Elliot is a graduate of Southern Methodist University and Washington University in St. Louis – Olin Business School.

Reesa Sherin is Carevive’s Clinical Strategist and is a MSN and RN. She has been with the company for six years and is a graduate of Temple University and Thomas Jefferson University.

April Boyd is the Clinical Product Manager at Carevive and has been in that role for three years now. Prior to that she worked at the MD Anderson Cancer Center.

Carevive

Part of this channel

Carevive

Remote oncology monitoring that connects clinicians and cancer patients between visits.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

The EU’s MDR delay buys time, but it won’t clear your commissioning bottleneck

The European Commission backed extending EU MDR transition deadlines to December 2027 and December 2028, Medical Design & Outsourcing reported. It buys time, not ramp-up capacity. Design News cites digital commissioning and machine digital twins to cut “power-on” surprises and speed validation and operator training.

  • 01If an EU portfolio includes Class III, December 2027 is now the planning anchor, but the internal gating item may shift to validation capacity and automation readiness, not paperwork.
  • 02Digital commissioning is becoming a procurement spec, not a buzzword, because it lets teams run DFM/DFA learning loops before hardware is built, which Design News notes is meant to reduce machine power-on surprises.

Sep 5, 2026

HCA’s Q1 was not about volume. It was about coverage and collecting cash

HCA Healthcare reaffirmed 2026 guidance after Q1 weather and a muted respiratory season cut adjusted EBITDA by about $180 million, according to HealthLeaders and Fierce Healthcare. Payer mix shifted fast. Exchange admissions fell about 15% and uninsured admissions rose about 16%, Fierce reported.

  • 01A mild flu season can be a margin event: HCA tied a 42% drop in respiratory admissions to a roughly $180M adjusted EBITDA hit (HealthLeaders, Fierce Healthcare).
  • 02The 2026 risk is sliding from demand to coverage: HCA cited a $600M–$900M full-year EBITDA headwind from exchange-related changes, with $150M already in Q1 (HealthLeaders, Fierce Healthcare).
  • 03Supplemental payments are becoming an operating capability, not a windfall: HCA said Q1 Medicaid program net benefit was about $200M vs $80M expected (HealthLeaders, Fierce Healthcare), putting state-by-state reimbursement strategy on the CFO’s critical path.

Sep 5, 2026

Dental practice exits are turning into multi-year projects, not last-year decisions

Dental practice exits are turning into multi-year projects, not last-year decisions

Associate-led dental practice successions can take 3–5+ years. Dental Economics says associate-to-buyout timelines often run three to five-plus years. That pushes revenue-cycle controls, buy-sell terms, and tax structure earlier, before a buyer appears.

  • 01A practical benchmark is emerging for succession: bringing in an associate with intent to buy can take a minimum of three years and often more than five, according to Dental Economics.
  • 02If accounts receivable looks “high,” it may be a bookkeeping and posting problem before it is a payer problem, a revenue-cycle diagnostic Group Dentistry Now says shows up frequently at scale.
  • 03Exit planning is now an operating system project: valuation, tax positioning, and transition support belong in the same workstream, because deal structure can lock in or foreclose tax options, per Dental Economics.

Sep 4, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512